ARTIOS PHARMA
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
ARTIOS PHARMA
Industry:
Biopharma Biotechnology Medical Device
Founded:
2016-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.artiospharma.com
Total Employee:
11+
Status:
Active
Contact:
+4401223804180
Email Addresses:
[email protected]
Total Funding:
298.28 M USD
Technology used in webpage:
Domain Not Resolving YouTube
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
KSQ Therapeutics
KSQ Therapeutics is using CRISPR technology within a powerful drug discovery engine to enable high-confidence drug development.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Avidity Partners
Avidity Partners investment in Series C - Artios Pharma
Andera Partners
Andera Partners investment in Series C - Artios Pharma
M Ventures
M Ventures investment in Series C - Artios Pharma
Tetragon Financial Group Limited
Tetragon Financial Group Limited investment in Series C - Artios Pharma
Soleus Capital
Soleus Capital investment in Series C - Artios Pharma
Arix Bioscience
Arix Bioscience investment in Series C - Artios Pharma
RTW Investments
RTW Investments investment in Series C - Artios Pharma
CaaS Capital Management
CaaS Capital Management investment in Series C - Artios Pharma
Deep Track Capital
Deep Track Capital investment in Series C - Artios Pharma
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - Artios Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2024-02-07 | Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer |
Official Site Inspections
http://www.artiospharma.com
- Host name: ec2-52-56-216-194.eu-west-2.compute.amazonaws.com
- IP address: 52.56.216.194
- Location: London United Kingdom
- Latitude: 51.5164
- Longitude: -0.093
- Timezone: Europe/London
- Postal: EC2V
More informations about "Artios Pharma"
DNA Damage Response | DDR Company | Artios Pharma
Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD. Quick Links. Homepage; Company; Science; Our Investors; News & Events; Careers & Culture; Contact …See details»
Artios Pharma - Crunchbase Company Profile & Funding
Artios Pharma — Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 …See details»
Artios Pharma Ltd - Company Profile & Staff Directory - ContactOut
Artios Pharma Ltd is a Biotechnology company located in The Glenn Berge Building, Babraham Research Campus, Cambridge, GB with 99 employees. Access Artios Pharma Ltd's email …See details»
ARTIOS PHARMA LIMITED Company Profile - Dun & Bradstreet
Artios pharma limited. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united kingdom / …See details»
Artios Pharma CEO and Key Executive Team | Craft.co
Artios Pharma's Chief Executive Officer and Director is Niall Martin. Other executives include Graeme Smith, Chief Scientific Officer; Ian Smith, Chief Medical Officer and 19 others. See the …See details»
Artios Pharma - Board and Governance - The Org
The Board and Governance team at Artios Pharma is responsible for overseeing the strategic direction and ethical standards of the company. This team collaborates with the Board of …See details»
Artios Pharma — Sofinnova Partners
Artios Pharma Limited is a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the …See details»
Artios Pharma - Craft
Artios Pharma Summary. Company Summary. Overview. Artios is a leading independent DNA Damage Response (DDR) company focussed on developing first-in-class treatments for …See details»
Artios Pharma - The Org
Artios Pharma is a company focused on developing novel cancer treatments targeting the DNA Damage Response #DDRSee details»
Artios Pharma - businessweekly.co.uk
Feb 8, 2025 Courtesy – Artios Pharma Artios has raised $320m to date from investors and strategic partners, including a $153m Series C financing in July 2021. The company has strategic partnerships with Merck KGaA and Novartis …See details»
Artios Pharma Company Profile: Funding, Investors & Partnerships
Oct 15, 2022 Artios Pharma. Submit feedback Claim this profile. Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for …See details»
Artios Pharma - Contacts, Employees, Board Members
Organization. Artios Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Artios Pharma has 8 current employee …See details»
Artios Pharma - EU-Startups
Artios Pharma. Category. UK. Business Description. Artios is a prominent independent DNA Damage Response (DDR) firm dedicated to the development of first-in-class cancer …See details»
Artios 2025 Company Profile: Valuation, Funding & Investors
Artios General Information Description. Developer of novel cancer treatments designed to target deoxyribonucleic acid (DNA) damage response. The company's treatments focus on …See details»
Artios Company Overview, Contact Details & Competitors | LeadIQ
Jul 27, 2021 Artios Pharma Ltd hired Samantha Truex as Board of Directors on Jun 15th '22. Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development …See details»
Artios Pharma's CEO and Executive Team Team - The Org
The current executive team at Artios Pharma has a wealth of experience in the finance and pharmaceutical industries. The team includes the former Chief Financial Officer at Precision …See details»
News & Events - Artios Pharma
Feb 7, 2024 News and Events. Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer …See details»
Artios Pharma - EQT Group
Do You Want to Know More? We are eager to explore how we can achieve great things together.See details»
Artios Artios - Arix Bioscience
Feb 9, 2023 Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients. Portfolio Company. 12th January 2021. Artios Pharma …See details»
Artios Pharma Reports Differentiated Clinical Activity in ... - BioSpace
3 days ago The Phase 1/2a trial for ART0380 is conducted with SCRI’s contract research organization, SCRI Development Innovations. Based on the meaningful clinical responses …See details»